| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/E04G19-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate |
2004-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2006-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2006528679-A |
| titleOfInvention |
Compositions and methods for treating coronavirus infections and sares |
| abstract |
The present invention relates to a method for treating coronavirus infection and a method for reducing virus filling or reducing virus clearance time or reducing morbidity and mortality in clinical outcomes in patients suffering from coronavirus infection. provide. The present invention further provides a method of reducing the risk that an individual will develop a pathological coronavirus infection with clinical sequelae. The present invention further provides a method for reducing the risk of an individual developing sars. The present invention further provides a method for treating Saas. The method generally involves administering a therapeutically effective amount of a type I or type III interferon receptor agonist and / or type II interferon receptor agonist for the treatment of a coronavirus infection. |
| priorityDate |
2003-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |